• GSK J4 HCl: Advancing Translational Epigenetics from Bench t

  2026-06-03

  This thought-leadership article explores how GSK J4 HCl, a potent JMJD3 inhibitor, is redefining experimental and translational strategies in epigenetic regulation research. Integrating mechanistic insights—such as the role of H3K27 methylation in immune modulation at the maternal-fetal interface—with strategic protocol guidance, it offers translational researchers actionable direction for leveraging this compound in inflammation, oncology, and reproductive biology. The piece stands apart by critically analyzing recent advances, referencing pivotal findings, and highlighting APExBIO's pivotal role in the evolving competitive landscape.

• GW4064: Non-Steroidal FXR Agonist Workflows in Metabolic Res

  2026-06-03

  GW4064 empowers precision FXR activation for dissecting bile acid, cholesterol, and triglyceride regulation in advanced metabolic and fibrotic models. This guide decodes experimental setups, troubleshooting, and cutting-edge applications—bridging recent breakthroughs with practical bench protocols.

• Advanced In Vitro Methods for Evaluating Cancer Drug Respons

  2026-06-02

  Schwartz's dissertation introduces rigorous in vitro methodologies that distinguish between proliferative arrest and cell death in cancer drug response evaluation. These refined approaches clarify drug mechanisms—enabling more precise assessment of agents like Foretinib (GSK1363089)—and improve translational relevance for oncology research.

• Dimetridazole: Protocol Optimization for Antimicrobial Assay

  2026-06-02

  Dimetridazole (1,2-Dimethyl-5-nitroimidazole) delivers robust, reproducible inhibition of anaerobic bacteria and protozoa, while uniquely suppressing quorum sensing and biofilm formation. This guide details advanced protocols, troubleshooting insights, and cross-domain applications that leverage Dimetridazole’s multifaceted research value.

• Angiotensin III (human, mouse): Molecular Insights and Trans

  2026-06-01

  Explore the advanced molecular functions of Angiotensin III in cardiovascular and neuroendocrine research. This article highlights the peptide’s unique receptor interactions, practical assay guidance, and implications for translational models, offering actionable perspectives beyond standard reviews.

• EZH2 Upregulation in ACC Microglia Drives Neuropathic Pain v

  2026-06-01

  This study reveals that elevated EZH2 in anterior cingulate cortex microglia exacerbates neuropathic pain after brachial plexus avulsion in rats by suppressing autophagy through MTOR signaling. The findings provide mechanistic insight into how epigenetic regulation in microglia contributes to neuroinflammation and pain, highlighting potential therapeutic targets for neuropathic pain management.

• Icariin Targets PDE5A to Enhance Spermatogonial Stem Cell Vi

  2026-05-31

  This study demonstrates that Icariin, a compound from traditional Chinese medicine, directly targets PDE5A to promote proliferation and DNA synthesis while reducing DNA damage in mouse spermatogonial stem cells. These findings clarify a novel molecular mechanism for improving male reproductive capacity and suggest new avenues for future fertility research.

• Jiedu Xiaozheng Yin Drives M1 Macrophage Polarization in CAC

  2026-05-30

  Liu et al. demonstrate that Jiedu Xiaozheng Yin (JXY), a traditional Chinese medicine formula, suppresses colitis-associated colorectal cancer (CAC) progression by stimulating M1 macrophage polarization through the TLR4 pathway. These findings highlight the potential of targeting innate immune cell phenotypes in the tumor microenvironment to impede cancer development.

• MK-2206 dihydrochloride: Optimizing PI3K/Akt Pathway Assays

  2026-05-29

  MK-2206 dihydrochloride enables precise, reproducible inhibition of Akt signaling for advanced apoptosis, angiogenesis, and pathway modulation studies. This guide translates recent workflow innovations, including those from sEV-CD147 angiogenesis research, into actionable protocols and troubleshooting strategies for cancer and PI3K/Akt/mTOR research.

• Metronidazole: Advanced OAT3 Inhibition and Microbiota Modul

  2026-05-29

  Explore how Metronidazole, a potent OAT3 inhibitor, enables precise research on drug-drug interactions and anaerobic bacteria targeting. This article offers a deeper look at microbiota modulation and assay design, uniquely integrating recent immunological findings.

• Dissecting Drug-Induced Growth Inhibition and Cell Death in

  2026-05-28

  Schwartz's dissertation systematically distinguishes between proliferation arrest and cell death in cancer drug response, clarifying the interpretation of in vitro viability metrics. This approach aids researchers in designing more informative assays and selecting inhibitors such as Foretinib (GSK1363089) for nuanced mechanistic studies.

• Lnc21q22.11 Suppresses Gastric Cancer via MEK/ERK Pathway In

  2026-05-28

  The referenced study identifies Lnc21q22.11 as a novel long non-coding RNA that inhibits gastric cancer growth by suppressing the MEK/ERK signaling pathway. These findings provide new mechanistic insights into lncRNA-mediated tumor suppression and highlight potential targets for therapeutic intervention.

• mRNA Encapsulation and Delivery Using ZIF-8 MOFs: New Strate

  2026-05-27

  The reference study demonstrates a pioneering approach for encapsulating and delivering mRNA using zeolitic imidazole framework-8 (ZIF-8) metal-organic frameworks. By integrating polyethyleneimine, the method achieves improved mRNA stability, robust intracellular protein expression, and even enables room-temperature storage, offering new avenues for non-viral gene delivery research.

• Radicicol: Unveiling Hsp90 Inhibition in Adipogenesis and Se

  2026-05-27

  Discover how Radicicol, a potent Hsp90 inhibitor, redefines research in adipogenesis, apoptosis, and inflammation. This article uniquely connects mechanistic insights with translational applications, offering guidance beyond protocol workflows.

• Berberine Hydrochloride Induces Tuft Cell Expansion to Count

  2026-05-26

  The reference study uncovers a novel mechanism by which berberine ameliorates estrogen deficiency-induced bone loss through induction of intestinal tuft cell expansion, mediated by butyrate-GPR41 signaling. These findings provide new insight into the gut-bone axis and suggest promising directions for postmenopausal osteoporosis research using berberine as a metabolic modulator.

14417 records 1/962 page Next 12345 下5页 Last page